RECRUITING

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Official Title

Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD

Quick Facts

Study Start:2023-11-03
Study Completion:2029-05-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06126341

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of Multiple Myeloma after January 1, 2017.
  2. * Karnofsky Performance Status \> 70%
  3. * ≥ 2 lines of prior therapy
  4. * Anticipated to start new a line of therapy for RRMM within the next 12 months
  5. * Age 18-80 years of age.
  6. * English or Spanish speaking.
  7. * Willing to provide informed consent
  8. * Willing to perform study procedures.
  9. * Be a Co-Investigator
  10. * Agree to comply with study procedures
  1. * Active CNS disease
  2. * Patients who already have a definitive plan are to be excluded

Contacts and Locations

Study Contact

Heather Landau, MD
CONTACT
646-608-3740
ABMTTrials@mskcc.org
Carlyn Tan, MD
CONTACT
646-608-3778
ABMTTrials@mskcc.org

Principal Investigator

Heather Landau, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
United States
Memorial Sloan Kettering Commack
Commack, New York, 11725
United States
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Heather Landau, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-03
Study Completion Date2029-05-03

Study Record Updates

Study Start Date2023-11-03
Study Completion Date2029-05-03

Terms related to this study

Keywords Provided by Researchers

  • Multiple Myeloma
  • BCMA CAR T-cell therapy
  • HCT
  • Memorial Sloan Kettering Cancer Center
  • 23-166

Additional Relevant MeSH Terms

  • Multiple Myeloma